⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AVXL News
Anavex Life Sciences
Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
globenewswire.com
AVXL
Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program
globenewswire.com
AVXL
Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer’s Disease Trial
globenewswire.com
AVXL